NDAORALTABLETPriority Review
Approved
May 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
LITHOSTAT (acetohydroxamic acid) by Mission Therapeutics is urease inhibitors [moa]. First approved in 1983.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LITHOSTAT (acetohydroxamic acid) is an oral urease inhibitor approved in 1983 for the prevention and treatment of uric acid and struvite kidney stones caused by urease-producing bacteria. It works by inhibiting bacterial urease, reducing ammonia production and stone formation in patients with recurrent infections or anatomic abnormalities.
$0.572MPart D
LOE ApproachingStable
Minimal commercial activity with only 1,238 Part D claims annually signals a niche, maintenance-mode product with small team requirements.
Mechanism of Action
Urease Inhibitors
Pharmacologic Class:
Urease Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LITHOSTAT shows zero linked job openings, reflecting its niche market status and minimal commercial scale. Careers tied to this product are limited to small, maintenance-focused teams managing a legacy specialty product.
Company
Worked on LITHOSTAT at Mission Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.